|
WO2011035417A1
|
|
Hsp-90 binding compounds, compositions thereof, and their use fn the treatment of autoimmune and inflammatory diseases
|
|
WO2011035416A1
|
|
Hsp90 modulating compounds, compositions, methods and uses
|
|
WO2010031171A1
|
|
Iap bir domain binding compounds
|
|
WO2010015090A1
|
|
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
WO2009155709A1
|
|
Bridged secondary amines and use thereof as iap bir domain binding compounds
|
|
US2011117081A1
|
|
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
WO2008144925A1
|
|
Iap bir domain binding compounds
|
|
MX2008014502A
|
|
Iap bir domain binding compounds.
|
|
CN101437513A
|
|
Use of imidazo[2,1-b)]-1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain
|
|
BRPI0710133A2
|
|
use of imidazo [2,1-b] -1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain
|
|
CN101443309A
|
|
IAP BIR domain binding compounds
|
|
WO2007101347A1
|
|
Bir domain binding compounds
|
|
NZ570152A
|
|
XAF-1, a diagnostic marker for interferon responsiveness in multiple sclerosis
|
|
EP1991693A1
|
|
Method for differentiating between multiple sclerosis subtypes
|
|
WO2007087716A1
|
|
Assay for identifying inhibitors of neuronal apoptotic pathways
|
|
CN101360728A
|
|
Iap bir domain binding compounds
|
|
CA2564872A1
|
|
Iap bir domain binding compounds
|
|
WO2006060898A1
|
|
Method for treating inflammatory disorders
|
|
WO2006039792A1
|
|
Method of treating autoimmune diseases
|
|
EP1682565A1
|
|
Iap nucleobase oligomers and oligomeric complexes and uses thereof
|
